A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition

BACKGROUND: Vascular endothelial growth factor (VEGF)-targeting drugs normalise the tumour vasculature and improve access for chemotherapy. However, excessive VEGF inhibition fails to improve clinical outcome, and successive treatment cycles lead to incremental extracellular matrix (ECM) deposition,...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiffmann, L M, Brunold, M, Liwschitz, M, Goede, V, Loges, S, Wroblewski, M, Quaas, A, Alakus, H, Stippel, D, Bruns, C J, Hallek, M, Kashkar, H, Hacker, U T, Coutelle, O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344294/
https://www.ncbi.nlm.nih.gov/pubmed/28141797
http://dx.doi.org/10.1038/bjc.2017.13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344294/
https://www.ncbi.nlm.nih.gov/pubmed/28141797
http://dx.doi.org/10.1038/bjc.2017.13

Ejemplares similares